Shares of Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) were up 3.3% during mid-day trading on Thursday . The stock traded as high as $36.01 and last traded at $35.92, with a volume of 619,099 shares. The stock had previously closed at $34.78.

Several analysts have recently issued reports on PCRX shares. Canaccord Genuity reiterated a “buy” rating on shares of Pacira Pharmaceuticals in a research note on Wednesday, April 20th. BMO Capital Markets started coverage on shares of Pacira Pharmaceuticals in a research note on Tuesday, June 28th. They issued an “underperform” rating and a $36.00 target price for the company. Mizuho started coverage on shares of Pacira Pharmaceuticals in a research note on Tuesday, April 19th. They issued a “buy” rating and a $79.00 target price for the company. Wedbush reiterated an “outperform” rating and issued a $105.00 target price on shares of Pacira Pharmaceuticals in a research note on Wednesday, June 22nd. Finally, Zacks Investment Research upgraded shares of Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, April 26th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the company’s stock. Pacira Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $78.15.

The firm’s market cap is $1.33 billion. The company’s 50 day moving average is $40.46 and its 200-day moving average is $53.20.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings data on Monday, May 2nd. The company reported $0.15 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.07 by $0.08. The firm had revenue of $65.50 million for the quarter, compared to analysts’ expectations of $67.11 million. During the same period last year, the company earned $0.27 earnings per share. The firm’s revenue was up 12.3% on a year-over-year basis. On average, analysts anticipate that Pacira Pharmaceuticals Inc. will post $0.38 EPS for the current year.

In other news, CAO Kristen Marie Williams sold 600 shares of the business’s stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $47.20, for a total transaction of $28,320.00. Following the transaction, the chief accounting officer now owns 6,900 shares of the company’s stock, valued at approximately $325,680. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Lauren Bullaro Riker sold 938 shares of the business’s stock in a transaction that occurred on Tuesday, June 7th. The shares were sold at an average price of $47.66, for a total value of $44,705.08. Following the transaction, the vice president now directly owns 5,945 shares in the company, valued at approximately $283,338.70. The disclosure for this sale can be found here.

Other institutional investors recently added to or reduced their stakes in the company. Russell Frank Co increased its position in Pacira Pharmaceuticals by 934.0% in the fourth quarter. Russell Frank Co now owns 82,720 shares of the company’s stock valued at $6,371,000 after buying an additional 74,720 shares in the last quarter. American Century Companies Inc. increased its position in Pacira Pharmaceuticals by 61.2% in the fourth quarter. American Century Companies Inc. now owns 66,438 shares of the company’s stock valued at $5,102,000 after buying an additional 25,215 shares in the last quarter. California State Teachers Retirement System increased its position in Pacira Pharmaceuticals by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 67,498 shares of the company’s stock valued at $5,183,000 after buying an additional 1,040 shares in the last quarter. Stephens Investment Management Group LLC increased its position in Pacira Pharmaceuticals by 10.0% in the fourth quarter. Stephens Investment Management Group LLC now owns 540,687 shares of the company’s stock valued at $41,519,000 after buying an additional 49,018 shares in the last quarter. Finally, OppenheimerFunds Inc. bought a new position in Pacira Pharmaceuticals during the fourth quarter valued at $10,171,000.

Pacira Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.